Clinical Trials
11
7 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
N/A
Active, not recruiting
7
63.6%
Completed
3
27.3%
Withdrawn
1
9.1%
No approval data available
- DelveInsight's 2025 pipeline report reveals over 30 companies are actively developing more than 40 therapies for myocardial infarction treatment across various clinical stages. - Key late-stage developments include Faraday Pharmaceuticals' FDY-5301 in Phase III trials and Acticor Biotech's Glenzocimab in Phase II, targeting different mechanisms of cardiac injury prevention. - Recent clinical milestones include Faraday's completion of patient enrollment in its pivotal Phase III trial and mixed results from other advanced programs like CSL112's failed Phase III endpoint. - The pipeline encompasses diverse therapeutic approaches including anti-ischemic agents, platelet inhibitors, and SGLT2 inhibitors, addressing various aspects of myocardial infarction pathophysiology.
- DelveInsight's 2025 analysis reveals over 20 key companies are developing 25+ acute ischemic stroke therapies across various clinical phases, representing significant advancement in stroke treatment research. - Recent clinical trials demonstrate promising results, including the ASSET-IT trial showing 65.9% excellent recovery rates with tirofiban combination therapy compared to 54.9% with placebo. - Multiple FDA designations have been granted, including Fast Track status for PP-007 and Orphan Drug Designation for CIRARA, accelerating development timelines for innovative stroke treatments. - The pipeline encompasses diverse therapeutic approaches including monoclonal antibodies, small molecules, and cell therapies, targeting various mechanisms from neuroprotection to thrombolysis enhancement.
- Acticor Biotech is focusing on myocardial infarction with glenzocimab, encouraged by expert feedback on its potential in STEMI treatment. - The LIBERATE phase 2b study, in partnership with the University of Birmingham, is ongoing, assessing glenzocimab's impact on infarct size in 212 STEMI patients. - A new phase 2 study, GLORIA, is being prepared to evaluate glenzocimab in approximately 300 STEMI patients, aiming for Phase 3 readiness by 2027. - Patient recruitment for GLORIA could begin in Q1 2025, contingent on the company's financial status and ongoing receivership procedure.
